TEL AVIV - Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), an Israel-based biopharmaceutical company, has announced the grant of a European patent for a combination therapy using its drug Aramchol and Resmetirom for treating liver diseases including NASH/MASH and liver fibrosis.
The patent covers France, Germany, Italy, the Netherlands, and the United Kingdom, with a pending approval in the United States and other countries. This development extends the patent protection of Aramchol, Galmed's lead compound, until September 2039.
The company has previously reported favorable results from the Open-Label part of its Phase 3 NASH study, where Aramchol 300mg BID showed a high rate of fibrosis improvement. Galmed's strategy has been to pursue combination therapy as the optimum treatment for NASH/MASH, a chronic liver condition characterized by excessive liver fat, high glycemic index, and fibrosis. Aramchol's mechanism, which down-regulates the expression and activity of stearoyl-CoA desaturase-1 (SCD1) in hepatic stellate cells, is posited to be a potent anti-fibrotic when used with other selective compounds.
Allen Baharaff, CEO and President of Galmed, expressed confidence in the combination therapy, stating that it aligns with the company's vision and previous patents granted in the U.S. for hepatic fibrosis treatment. Galmed's focus remains on the development of Aramchol for various liver and fibro-inflammatory diseases, including a collaboration with the Hebrew University on Amilo-5MER, a synthetic peptide.
This news is based on a press release statement from Galmed Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.